ArticleMedicine2026
The bidirectional causal relationships of insomnia with eleven cancers: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insomnia is closely associated with tumors and is recognized as a risk factor for cancer development. This two-sample Mendelian randomization (MR) study investigated the potential causal link between genetically determined insomnia and various cancers, including brain, colorectal, esophageal, gastric, hepatic bile duct, liver, lung, malignant lymphoma, pancreatic, skin, and thyroid cancers. Summary statistics from genome-wide association studies for insomnia and eleven cancer types were examined. instrumental variables (IVs) were selected from single nucleotide polymorphisms that passed strict quality control for minimal linkage disequilibrium and genome-wide significance. All IVs demonstrated strong predictive power for insomnia, with F-statistics exceeding the conventional threshold of 10. The primary analysis was conducted using the inverse variance weighted method. Sensitivity analyses were performed using MR-Egger regression, weighted median, and weighted mode methods to test robustness, pleiotropy, and heterogeneity. MR analysis suggested potential causal associations between insomnia and increased risk of hepatic bile duct cancer (odds ratio [OR] = 4.458, 95% confidence interval [CI]: 1.074-18.493, P = .040), reduced risk of hepatic cancer (OR = 0.312, 95% CI: 0.100-0.973, P = .045), and reduced risk of skin cancers (OR = 0.599, 95% CI: 0.439-0.818, P = .001). However, after Bonferroni correction (adjusted threshold P < .0045), these associations did not retain statistical significance. No notable causal influence of these cancers on insomnia was observed. Sensitivity analyses showed no evidence of reverse causality or significant bias. These findings, though not retaining statistical significance after stringent multiple testing correction, provide suggestive evidence that genetically predicted insomnia may influence the risk of certain cancers, potentially through mechanisms involving genetic predisposition and biological pathways that modulate inflammation, immune function, and circadian rhythms. The study highlights the translational value of understanding insomnia's role in cancer risk, suggesting that clinicians should consider this association when managing patients with insomnia. Further research with larger sample sizes is warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.